2014
Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia
Publication
Publication
OncoImmunology , Volume 3 - Issue 12 p. 1- 3
The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.
| Additional Metadata | |
|---|---|
| , , , , | |
| doi.org/10.4161/21624011.2014.941737, hdl.handle.net/1765/88237 | |
| OncoImmunology | |
| Organisation | Department of Immunology |
|
van Luijn, M., van den Ancker, W., van Ham, M., & van de Loosdrecht, A. (2014). Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. OncoImmunology, 3(12), 1–3. doi:10.4161/21624011.2014.941737 |
|